ABCSG 57 / ALPHABET Overview


A randomized phase III trial of trastuzumab + alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ advanced breast cancer

Study Start: AT: 09/2022
Global: 10/2021; FPI 10/2021
Coordinating Investigator: AT: Marija Balic, Graz
Sample Size: AT: 30
Global: 252
Study Design:
(Click to enlarge)
ABCSG 57 / ALPHABET


Share on


Top